# Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers

> **NCT01448317** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 32 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Alirocumab (Solution)
- **DRUG:** Alirocumab (Lyophilized formulation)
- **DRUG:** Placebo (Solution)
- **DRUG:** Placebo (Lyophilized formulation)

## Key facts

- **NCT ID:** NCT01448317
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01448317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01448317, "Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01448317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*